Share Price and Basic Stock Data
Last Updated: January 22, 2026, 8:19 pm
| PEG Ratio | 0.30 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Entero Healthcare Solutions Ltd operates in the pharmaceuticals sector and reported a share price of ₹1,110 with a market capitalization of ₹4,830 Cr. The company’s revenue has shown a consistent upward trend, with sales increasing from ₹3,300 Cr in FY 2023 to ₹5,096 Cr in FY 2025, reflecting a significant growth trajectory. The trailing twelve months (TTM) revenue stood at ₹5,673 Cr, indicating strong operational performance. Quarterly sales figures also demonstrate this growth, with sales rising from ₹829 Cr in December 2022 to ₹1,571 Cr by September 2025. This growth is indicative of Entero’s expanding market presence and effective sales strategies. However, the company’s operating profit margins (OPM) were relatively low, recorded at 4% in the latest figures, suggesting room for improvement in cost management and operational efficiency compared to industry standards.
Profitability and Efficiency Metrics
Entero Healthcare reported a net profit of ₹128 Cr for FY 2025, showcasing a recovery from previous losses, with net profit margins improving to 2.1%. The operating profit for FY 2025 reached ₹172 Cr, reflecting a healthy increase from ₹64 Cr in FY 2023. Despite these positive trends, the return on equity (ROE) stood at a modest 5.63%, below the sector average, indicating less effective equity utilization. The interest coverage ratio (ICR) at 5.07x suggests that the company comfortably meets its interest obligations, a positive sign for creditors. However, the cash conversion cycle (CCC) of 80 days highlights inefficiencies in managing receivables and inventory, which could impact liquidity. Overall, while profitability is on the rise, the efficiency ratios reveal areas that require strategic focus to enhance overall financial health.
Balance Sheet Strength and Financial Ratios
As of FY 2025, Entero Healthcare’s balance sheet exhibited a robust position with total assets amounting to ₹2,703 Cr and reserves of ₹1,723 Cr, reflecting a healthier equity base compared to previous years. The company’s borrowings stood at ₹443 Cr, allowing for a manageable total debt-to-equity ratio of 0.17, indicating low leverage levels. The price-to-book value (P/BV) ratio of 2.87x indicates that the stock may be overvalued relative to its book value, which could be a concern for investors. The current ratio of 2.46x and quick ratio of 1.68x suggest strong liquidity, enabling the company to cover short-term obligations effectively. However, the low return on capital employed (ROCE) at 8.71% indicates that the capital invested in the business is not generating commensurate returns, which could deter potential investors looking for high efficiency.
Shareholding Pattern and Investor Confidence
Entero Healthcare’s shareholding pattern indicates a significant promoter holding of 52.42%, reflecting strong management control over the company. Foreign institutional investors (FIIs) hold 14.68%, which has declined from 23.30% in March 2024, suggesting a reduction in foreign investor confidence. Domestic institutional investors (DIIs) hold 9.64%, while the public holds 23.26% of shares. The number of shareholders has risen to 36,334, indicating increasing retail investor interest. This pattern suggests a mixed sentiment among institutional investors, which could impact stock liquidity and market volatility. The decline in FII participation may raise concerns about the company’s attractiveness to foreign capital, necessitating a focus on enhancing operational performance to regain investor trust.
Outlook, Risks, and Final Insight
Looking ahead, Entero Healthcare has the potential for continued revenue growth driven by its expanding market footprint. However, several risks loom, including potential fluctuations in operational efficiency, as evidenced by the CCC and ROCE figures. Additionally, the company’s reliance on external financing could pose risks if interest rates rise or market conditions deteriorate. The decline in FII interest may also affect stock performance if not addressed. To mitigate these risks, Entero should focus on improving operational efficiencies and enhancing profitability margins. Should the company successfully implement strategies to improve its operational metrics and regain investor confidence, it could position itself favorably for future growth and value creation in the competitive pharmaceuticals sector.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 123 Cr. | 98.0 | 203/84.3 | 27.3 | 49.6 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.21 Cr. | 1.68 | 4.29/1.68 | 0.33 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 3,696 Cr. | 340 | 479/192 | 76.5 | 24.3 | 0.20 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 32.3 Cr. | 43.5 | 87.8/37.2 | 10.6 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 61.0 Cr. | 41.6 | 42.0/17.0 | 145 | 6.93 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 19,739.31 Cr | 1,099.94 | 48.35 | 202.32 | 0.38% | 16.29% | 15.20% | 6.10 |
Quarterly Result
| Metric | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 829 | 887 | 899 | 996 | 993 | 1,034 | 1,097 | 1,301 | 1,359 | 1,339 | 1,404 | 1,571 |
| Expenses | 810 | 867 | 873 | 968 | 964 | 1,005 | 1,067 | 1,258 | 1,309 | 1,290 | 1,354 | 1,509 |
| Operating Profit | 19 | 20 | 26 | 29 | 29 | 29 | 30 | 42 | 50 | 49 | 50 | 62 |
| OPM % | 2% | 2% | 3% | 3% | 3% | 3% | 3% | 3% | 4% | 4% | 4% | 4% |
| Other Income | 2 | 1 | 1 | 2 | 2 | 9 | 13 | 11 | 8 | 7 | 6 | 5 |
| Interest | 13 | 13 | 14 | 18 | 16 | 17 | 10 | 11 | 10 | 10 | 11 | 12 |
| Depreciation | 5 | 7 | 6 | 6 | 6 | 7 | 7 | 7 | 8 | 8 | 9 | 10 |
| Profit before tax | 2 | 1 | 7 | 7 | 8 | 14 | 27 | 35 | 39 | 37 | 36 | 45 |
| Tax % | -44% | 490% | 6% | 23% | 16% | -56% | 25% | 25% | 25% | 16% | 17% | 18% |
| Net Profit | 4 | -4 | 6 | 5 | 7 | 21 | 21 | 26 | 29 | 31 | 30 | 37 |
| EPS in Rs | 8.05 | -9.05 | 15.18 | 3.19 | 4.22 | 4.82 | 4.62 | 5.43 | 5.85 | 5.91 | 6.39 | 7.26 |
Last Updated: December 27, 2025, 2:37 am
Below is a detailed analysis of the quarterly data for Entero Healthcare Solutions Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Sales, as of Sep 2025, the value is 1,571.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,404.00 Cr. (Jun 2025) to 1,571.00 Cr., marking an increase of 167.00 Cr..
- For Expenses, as of Sep 2025, the value is 1,509.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 1,354.00 Cr. (Jun 2025) to 1,509.00 Cr., marking an increase of 155.00 Cr..
- For Operating Profit, as of Sep 2025, the value is 62.00 Cr.. The value appears strong and on an upward trend. It has increased from 50.00 Cr. (Jun 2025) to 62.00 Cr., marking an increase of 12.00 Cr..
- For OPM %, as of Sep 2025, the value is 4.00%. The value remains steady. There is no change compared to the previous period (Jun 2025) which recorded 4.00%.
- For Other Income, as of Sep 2025, the value is 5.00 Cr.. The value appears to be declining and may need further review. It has decreased from 6.00 Cr. (Jun 2025) to 5.00 Cr., marking a decrease of 1.00 Cr..
- For Interest, as of Sep 2025, the value is 12.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 11.00 Cr. (Jun 2025) to 12.00 Cr., marking an increase of 1.00 Cr..
- For Depreciation, as of Sep 2025, the value is 10.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 9.00 Cr. (Jun 2025) to 10.00 Cr., marking an increase of 1.00 Cr..
- For Profit before tax, as of Sep 2025, the value is 45.00 Cr.. The value appears strong and on an upward trend. It has increased from 36.00 Cr. (Jun 2025) to 45.00 Cr., marking an increase of 9.00 Cr..
- For Tax %, as of Sep 2025, the value is 18.00%. The value appears to be increasing, which may not be favorable. It has increased from 17.00% (Jun 2025) to 18.00%, marking an increase of 1.00%.
- For Net Profit, as of Sep 2025, the value is 37.00 Cr.. The value appears strong and on an upward trend. It has increased from 30.00 Cr. (Jun 2025) to 37.00 Cr., marking an increase of 7.00 Cr..
- For EPS in Rs, as of Sep 2025, the value is 7.26. The value appears strong and on an upward trend. It has increased from 6.39 (Jun 2025) to 7.26, marking an increase of 0.87.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 3:47 am
| Metric | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|
| Sales | 1,350 | 1,773 | 2,522 | 3,300 | 3,922 | 5,096 | 5,673 |
| Expenses | 1,326 | 1,758 | 2,498 | 3,236 | 3,810 | 4,924 | 5,462 |
| Operating Profit | 23 | 15 | 24 | 64 | 112 | 172 | 211 |
| OPM % | 2% | 1% | 1% | 2% | 3% | 3% | 4% |
| Other Income | 5 | 11 | 4 | 6 | 14 | 39 | 25 |
| Interest | 13 | 20 | 29 | 49 | 66 | 42 | 44 |
| Depreciation | 12 | 16 | 20 | 24 | 25 | 31 | 35 |
| Profit before tax | 4 | -11 | -20 | -4 | 36 | 139 | 158 |
| Tax % | 67% | 42% | 49% | 201% | -12% | 23% | |
| Net Profit | 1 | -15 | -29 | -11 | 40 | 107 | 128 |
| EPS in Rs | 93.81 | -1,550.90 | -77.71 | -28.12 | 8.99 | 21.80 | 25.41 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% |
YoY Net Profit Growth
| Year | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | -1600.00% | -93.33% | 62.07% | 463.64% | 167.50% |
| Change in YoY Net Profit Growth (%) | 0.00% | 1506.67% | 155.40% | 401.57% | -296.14% |
Entero Healthcare Solutions Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 5 years from 2020-2021 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 30% |
| 3 Years: | 26% |
| TTM: | 31% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 152% |
| 3 Years: | 73% |
| TTM: | 94% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | -17% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | 6% |
Last Updated: September 5, 2025, 3:26 pm
Balance Sheet
Last Updated: December 10, 2025, 4:15 am
| Month | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|
| Equity Capital | 0.10 | 0.10 | 4 | 4 | 43 | 44 | 44 |
| Reserves | -16 | -32 | -62 | -73 | 1,595 | 1,681 | 1,723 |
| Borrowings | 603 | 720 | 974 | 1,101 | 338 | 385 | 443 |
| Other Liabilities | 162 | 147 | 210 | 275 | 369 | 593 | 642 |
| Total Liabilities | 749 | 836 | 1,125 | 1,308 | 2,345 | 2,703 | 2,851 |
| Fixed Assets | 186 | 189 | 262 | 268 | 289 | 559 | 627 |
| CWIP | 2 | 2 | 1 | 0 | 0 | 0 | 0 |
| Investments | 0 | 0 | 0 | 0 | 0 | 58 | 67 |
| Other Assets | 560 | 645 | 863 | 1,040 | 2,056 | 2,085 | 2,158 |
| Total Assets | 749 | 836 | 1,125 | 1,308 | 2,345 | 2,703 | 2,851 |
Below is a detailed analysis of the balance sheet data for Entero Healthcare Solutions Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 44.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 44.00 Cr..
- For Reserves, as of Sep 2025, the value is 1,723.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,681.00 Cr. (Mar 2025) to 1,723.00 Cr., marking an increase of 42.00 Cr..
- For Borrowings, as of Sep 2025, the value is 443.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 385.00 Cr. (Mar 2025) to 443.00 Cr., marking an increase of 58.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 642.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 593.00 Cr. (Mar 2025) to 642.00 Cr., marking an increase of 49.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 2,851.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 2,703.00 Cr. (Mar 2025) to 2,851.00 Cr., marking an increase of 148.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 627.00 Cr.. The value appears strong and on an upward trend. It has increased from 559.00 Cr. (Mar 2025) to 627.00 Cr., marking an increase of 68.00 Cr..
- For CWIP, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Investments, as of Sep 2025, the value is 67.00 Cr.. The value appears strong and on an upward trend. It has increased from 58.00 Cr. (Mar 2025) to 67.00 Cr., marking an increase of 9.00 Cr..
- For Other Assets, as of Sep 2025, the value is 2,158.00 Cr.. The value appears strong and on an upward trend. It has increased from 2,085.00 Cr. (Mar 2025) to 2,158.00 Cr., marking an increase of 73.00 Cr..
- For Total Assets, as of Sep 2025, the value is 2,851.00 Cr.. The value appears strong and on an upward trend. It has increased from 2,703.00 Cr. (Mar 2025) to 2,851.00 Cr., marking an increase of 148.00 Cr..
Notably, the Reserves (1,723.00 Cr.) exceed the Borrowings (443.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|
| Free Cash Flow | -580.00 | -705.00 | -950.00 | 63.00 | -226.00 | -213.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|
| Debtor Days | 63 | 50 | 54 | 57 | 57 | 59 |
| Inventory Days | 57 | 54 | 49 | 41 | 43 | 52 |
| Days Payable | 32 | 22 | 22 | 25 | 24 | 31 |
| Cash Conversion Cycle | 88 | 82 | 81 | 73 | 77 | 80 |
| Working Capital Days | 57 | 54 | 41 | 32 | 48 | 65 |
| ROCE % | 1% | 1% | 5% | 7% | 9% |
Mutual Fund Holdings
| Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
|---|---|---|---|---|---|---|
| Invesco India Contra Fund | 1,577,379 | 0.81 | 167.63 | N/A | N/A | N/A |
| Invesco India ELSS Tax Saver Fund | 450,000 | 1.69 | 47.82 | N/A | N/A | N/A |
| Invesco India Aggressive Hybrid Fund | 30,000 | 0.38 | 3.19 | N/A | N/A | N/A |
| HSBC Tax Saver Equity Fund | 21,400 | 0.92 | 2.27 | N/A | N/A | N/A |
| Invesco India Equity Savings Fund | 17,000 | 0.43 | 1.81 | N/A | N/A | N/A |
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 21.80 | 10.81 | -3.10 | -9.22 | -5.29 |
| Diluted EPS (Rs.) | 21.76 | 10.81 | -3.10 | -9.22 | -5.29 |
| Cash EPS (Rs.) | 31.75 | 14.90 | 31.94 | -25.16 | 92.20 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 396.28 | 377.38 | -160.39 | -144.87 | -3005.20 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 396.28 | 377.38 | -160.39 | -144.87 | -3005.20 |
| Revenue From Operations / Share (Rs.) | 1171.23 | 901.80 | 8025.80 | 6550.82 | 177973.70 |
| PBDIT / Share (Rs.) | 48.51 | 29.03 | 169.07 | 75.12 | 2547.60 |
| PBIT / Share (Rs.) | 41.45 | 23.28 | 110.13 | 23.81 | 920.00 |
| PBT / Share (Rs.) | 31.89 | 8.17 | -8.97 | -51.46 | -1083.80 |
| Net Profit / Share (Rs.) | 24.69 | 9.15 | -27.00 | -76.46 | -1535.40 |
| NP After MI And SOA / Share (Rs.) | 21.79 | 8.99 | -28.11 | -77.71 | -1553.70 |
| PBDIT Margin (%) | 4.14 | 3.21 | 2.10 | 1.14 | 1.43 |
| PBIT Margin (%) | 3.53 | 2.58 | 1.37 | 0.36 | 0.51 |
| PBT Margin (%) | 2.72 | 0.90 | -0.11 | -0.78 | -0.60 |
| Net Profit Margin (%) | 2.10 | 1.01 | -0.33 | -1.16 | -0.86 |
| NP After MI And SOA Margin (%) | 1.86 | 0.99 | -0.35 | -1.18 | -0.87 |
| Return on Networth / Equity (%) | 5.49 | 2.38 | 0.00 | 0.00 | 0.00 |
| Return on Capital Employeed (%) | 9.70 | 5.80 | 6.61 | 1.38 | 1.68 |
| Return On Assets (%) | 3.50 | 1.66 | -0.88 | -2.65 | -1.86 |
| Long Term Debt / Equity (X) | 0.00 | 0.02 | -0.45 | -0.64 | 0.00 |
| Total Debt / Equity (X) | 0.17 | 0.16 | -5.45 | -4.92 | -4.46 |
| Asset Turnover Ratio (%) | 2.02 | 2.15 | 2.71 | 2.57 | 0.00 |
| Current Ratio (X) | 2.46 | 3.34 | 1.64 | 1.84 | 2.19 |
| Quick Ratio (X) | 1.68 | 2.64 | 1.09 | 1.17 | 1.35 |
| Inventory Turnover Ratio (X) | 9.43 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Coverage Ratio (X) | 5.07 | 1.92 | 1.42 | 0.99 | 1.27 |
| Interest Coverage Ratio (Post Tax) (X) | 3.58 | 1.61 | 0.77 | -0.01 | 0.23 |
| Enterprise Value (Cr.) | 5029.50 | 3669.42 | 0.00 | 0.00 | 0.00 |
| EV / Net Operating Revenue (X) | 0.98 | 0.93 | 0.00 | 0.00 | 0.00 |
| EV / EBITDA (X) | 23.83 | 29.06 | 0.00 | 0.00 | 0.00 |
| MarketCap / Net Operating Revenue (X) | 0.97 | 1.09 | 0.00 | 0.00 | 0.00 |
| Price / BV (X) | 2.87 | 2.62 | 0.00 | 0.00 | 0.00 |
| Price / Net Operating Revenue (X) | 0.97 | 1.09 | 0.00 | 0.00 | 0.00 |
| EarningsYield | 0.01 | 0.01 | 0.00 | 0.00 | 0.00 |
After reviewing the key financial ratios for Entero Healthcare Solutions Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 21.80. This value is within the healthy range. It has increased from 10.81 (Mar 24) to 21.80, marking an increase of 10.99.
- For Diluted EPS (Rs.), as of Mar 25, the value is 21.76. This value is within the healthy range. It has increased from 10.81 (Mar 24) to 21.76, marking an increase of 10.95.
- For Cash EPS (Rs.), as of Mar 25, the value is 31.75. This value is within the healthy range. It has increased from 14.90 (Mar 24) to 31.75, marking an increase of 16.85.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 396.28. It has increased from 377.38 (Mar 24) to 396.28, marking an increase of 18.90.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 396.28. It has increased from 377.38 (Mar 24) to 396.28, marking an increase of 18.90.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 1,171.23. It has increased from 901.80 (Mar 24) to 1,171.23, marking an increase of 269.43.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 48.51. This value is within the healthy range. It has increased from 29.03 (Mar 24) to 48.51, marking an increase of 19.48.
- For PBIT / Share (Rs.), as of Mar 25, the value is 41.45. This value is within the healthy range. It has increased from 23.28 (Mar 24) to 41.45, marking an increase of 18.17.
- For PBT / Share (Rs.), as of Mar 25, the value is 31.89. This value is within the healthy range. It has increased from 8.17 (Mar 24) to 31.89, marking an increase of 23.72.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 24.69. This value is within the healthy range. It has increased from 9.15 (Mar 24) to 24.69, marking an increase of 15.54.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 21.79. This value is within the healthy range. It has increased from 8.99 (Mar 24) to 21.79, marking an increase of 12.80.
- For PBDIT Margin (%), as of Mar 25, the value is 4.14. This value is below the healthy minimum of 10. It has increased from 3.21 (Mar 24) to 4.14, marking an increase of 0.93.
- For PBIT Margin (%), as of Mar 25, the value is 3.53. This value is below the healthy minimum of 10. It has increased from 2.58 (Mar 24) to 3.53, marking an increase of 0.95.
- For PBT Margin (%), as of Mar 25, the value is 2.72. This value is below the healthy minimum of 10. It has increased from 0.90 (Mar 24) to 2.72, marking an increase of 1.82.
- For Net Profit Margin (%), as of Mar 25, the value is 2.10. This value is below the healthy minimum of 5. It has increased from 1.01 (Mar 24) to 2.10, marking an increase of 1.09.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 1.86. This value is below the healthy minimum of 8. It has increased from 0.99 (Mar 24) to 1.86, marking an increase of 0.87.
- For Return on Networth / Equity (%), as of Mar 25, the value is 5.49. This value is below the healthy minimum of 15. It has increased from 2.38 (Mar 24) to 5.49, marking an increase of 3.11.
- For Return on Capital Employeed (%), as of Mar 25, the value is 9.70. This value is below the healthy minimum of 10. It has increased from 5.80 (Mar 24) to 9.70, marking an increase of 3.90.
- For Return On Assets (%), as of Mar 25, the value is 3.50. This value is below the healthy minimum of 5. It has increased from 1.66 (Mar 24) to 3.50, marking an increase of 1.84.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 0.2. It has decreased from 0.02 (Mar 24) to 0.00, marking a decrease of 0.02.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.17. This value is within the healthy range. It has increased from 0.16 (Mar 24) to 0.17, marking an increase of 0.01.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 2.02. It has decreased from 2.15 (Mar 24) to 2.02, marking a decrease of 0.13.
- For Current Ratio (X), as of Mar 25, the value is 2.46. This value is within the healthy range. It has decreased from 3.34 (Mar 24) to 2.46, marking a decrease of 0.88.
- For Quick Ratio (X), as of Mar 25, the value is 1.68. This value is within the healthy range. It has decreased from 2.64 (Mar 24) to 1.68, marking a decrease of 0.96.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 9.43. This value exceeds the healthy maximum of 8. It has increased from 0.00 (Mar 24) to 9.43, marking an increase of 9.43.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 5.07. This value is within the healthy range. It has increased from 1.92 (Mar 24) to 5.07, marking an increase of 3.15.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 3.58. This value is within the healthy range. It has increased from 1.61 (Mar 24) to 3.58, marking an increase of 1.97.
- For Enterprise Value (Cr.), as of Mar 25, the value is 5,029.50. It has increased from 3,669.42 (Mar 24) to 5,029.50, marking an increase of 1,360.08.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 0.98. This value is below the healthy minimum of 1. It has increased from 0.93 (Mar 24) to 0.98, marking an increase of 0.05.
- For EV / EBITDA (X), as of Mar 25, the value is 23.83. This value exceeds the healthy maximum of 15. It has decreased from 29.06 (Mar 24) to 23.83, marking a decrease of 5.23.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 0.97. This value is below the healthy minimum of 1. It has decreased from 1.09 (Mar 24) to 0.97, marking a decrease of 0.12.
- For Price / BV (X), as of Mar 25, the value is 2.87. This value is within the healthy range. It has increased from 2.62 (Mar 24) to 2.87, marking an increase of 0.25.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 0.97. This value is below the healthy minimum of 1. It has decreased from 1.09 (Mar 24) to 0.97, marking a decrease of 0.12.
- For EarningsYield, as of Mar 25, the value is 0.01. This value is below the healthy minimum of 5. There is no change compared to the previous period (Mar 24) which recorded 0.01.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Entero Healthcare Solutions Ltd:
- Net Profit Margin: 2.1%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 9.7% (Industry Average ROCE: 16.29%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 5.49% (Industry Average ROE: 15.2%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 3.58
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 1.68
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 46.2 (Industry average Stock P/E: 48.35)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.17
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 2.1%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | Plot No. I-35, Building - B, Industrial Area, Phase - I, Faridabad Haryana 121003 | Contact not found |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Sujesh Vasudevan | Chairperson (NonExe.&Ind.Director) |
| Mr. Prabhat Agrawal | Managing Director & CEO |
| Mr. Prem Sethi | Whole Time Director & COO |
| Mr. Rajesh Shashikant Dalal | Ind. Non-Executive Director |
| Ms. Sandhya Gadkari Sharma | Ind. Non-Executive Director |
| Mr. Arun Sadhanandham | Non Exe.Non Ind.Director |
| Ms. Sumona Chakraborty | Non Exe.Non Ind.Director |
| Mr. Kevin Rohitbhai Daftary | Non Exe.Non Ind.Director |
FAQ
What is the intrinsic value of Entero Healthcare Solutions Ltd?
Entero Healthcare Solutions Ltd's intrinsic value (as of 23 January 2026) is ₹2182.09 which is 85.39% higher the current market price of ₹1,177.00, indicating undervalued. Calculated using the PE ratio method, this valuation considers the company's ₹5,108 Cr. market cap, FY2025-2026 high/low of ₹1,565/944, reserves of ₹1,723 Cr, and liabilities of ₹2,851 Cr.
What is the Market Cap of Entero Healthcare Solutions Ltd?
The Market Cap of Entero Healthcare Solutions Ltd is 5,108 Cr..
What is the current Stock Price of Entero Healthcare Solutions Ltd as on 23 January 2026?
The current stock price of Entero Healthcare Solutions Ltd as on 23 January 2026 is ₹1,177.
What is the High / Low of Entero Healthcare Solutions Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Entero Healthcare Solutions Ltd stocks is ₹1,565/944.
What is the Stock P/E of Entero Healthcare Solutions Ltd?
The Stock P/E of Entero Healthcare Solutions Ltd is 46.2.
What is the Book Value of Entero Healthcare Solutions Ltd?
The Book Value of Entero Healthcare Solutions Ltd is 406.
What is the Dividend Yield of Entero Healthcare Solutions Ltd?
The Dividend Yield of Entero Healthcare Solutions Ltd is 0.00 %.
What is the ROCE of Entero Healthcare Solutions Ltd?
The ROCE of Entero Healthcare Solutions Ltd is 8.71 %.
What is the ROE of Entero Healthcare Solutions Ltd?
The ROE of Entero Healthcare Solutions Ltd is 5.63 %.
What is the Face Value of Entero Healthcare Solutions Ltd?
The Face Value of Entero Healthcare Solutions Ltd is 10.0.